Nicotine Science and Policy

The National Press Club discussion addressed Australia's illicit tobacco crisis, emphasizing the need to move beyond enforcement to consider broader policy implications. Speakers highlighted the unintended consequences of current strategies, including the role of public policy in fueling the illicit market. Different perspectives were presented, underscoring the need for a more comprehensive national strategy with measurable outcomes. The discussion also explored the intersection of science, regulation, and harm reduction in tobacco control. Ultimately, the event encouraged a reevaluation of Australia's approach to reducing smoking rates while addressing the complexities of the illicit tobacco trade and the need for evidence-based policy decisions.

Smoking among people who use drugs, such as heroin users in England, contributes significantly to premature deaths. Despite this, smoking is often overlooked in drug treatment services. David MacKintosh from the Global State of Tobacco Harm Reduction suggests incorporating safer nicotine options to improve health outcomes and longevity. Drug service providers face challenges in addressing smoking alongside drug issues due to resource constraints. Encouraging harm reduction services to consider smoking cessation could yield positive results. Smoking-related deaths in this population are comparable to drug-related deaths, highlighting the need for comprehensive support and awareness. The Global Forum on Nicotine fosters discussions on harm reduction approaches with a focus on consumer perspectives.

Smoking is not evenly distributed across society. It is increasingly concentrated among people facing poverty, stress and fewer routes to support — which means tobacco policy cannot be judged only by national averages. If lower-risk alternatives are made harder to access or understand, the burden will fall hardest on the people already most affected by smoking-related harm. A serious strategy must reduce risk without widening inequality.

Eight million pounds can buy a lot of public health activity. The harder question is whether it buys better outcomes. Funding should support evidence, transparency and interventions that help smokers move away from combustible tobacco — not campaigns that deepen confusion about lower-risk alternatives. In tobacco policy, spending money is not the same as reducing harm.

Heart risk is not shaped by nicotine alone. A review linking full switching from smoking to vaping with lower cardiovascular risk reinforces the central point of harm reduction: combustion is the major driver of disease. The distinction between dual use and complete switching also matters, because public health gains depend on moving away from cigarettes, not simply adding another product. Risk communication should be clear enough to help smokers understand that difference.